Nourianz (istradefylline) Approved as an Add-on Treatment in Parkinson Disease Nourianz (istradefylline) Approved as an Add-on Treatment in Parkinson Disease
This post was originally published on this site Latest Neurology News WEDNESDAY, Aug. 28, 2019 (HealthDay News) — Nourianz (istradefylline) tablets have been approved... Nourianz (istradefylline) Approved as an Add-on Treatment in Parkinson Disease
This post was originally published on this site

News Picture: Nourianz Approved to Treat 'Off' Episodes in Parkinson Disease

Latest Neurology News

WEDNESDAY, Aug. 28, 2019 (HealthDay News) — Nourianz (istradefylline) tablets have been approved as an add-on treatment to levodopa/carbidopa for adults with Parkinson disease experiencing “off” episodes, the U.S. Food and Drug Administration announced yesterday.

The drug is available in 20-mg or 40-mg doses, but the maximum recommended dosage in patients taking CYP3A4 inhibitors and those with moderate hepatic impairment is 20 mg once daily. The safety information for Nourianz states that use of the drug should be avoided in these patient populations.

Data from four 12-week placebo-controlled clinical studies demonstrated the effectiveness of Nourianz, a selective adenosine A2A receptor antagonist, in treating “off” episodes in 1,143 PD patients who were receiving treatment with levodopa/carbidopa. Compared with patients who received placebo, patients who received Nourianz experienced a statistically significant decrease in daily “off” time from baseline.

The most commonly reported adverse reactions with Nourianz included dyskinesia, dizziness, constipation, nausea, hallucination, and insomnia. The FDA noted that physicians should monitor patients for development or progression of dyskinesia while taking Nourianz. A reduction in dosage or stoppage of Nourianz should be considered in the case of hallucinations, psychotic behavior, or impulsive/compulsive behavior. Nourianz should not be used during pregnancy, and women with childbearing potential should use contraception during treatment.

Approval was granted to Kyowa Kirin.

More Information

MedicalNews
Copyright © 2019 HealthDay. All rights reserved.

QUESTION

Parkinson’s disease is only seen in people of advanced age. See Answer

Source: This post was originally published at MedicineNet on .

No comments so far.

Be first to leave comment below.

Your email address will not be published. Required fields are marked *